intraderm
id
vaccin
offer
improv
immun
simpler
logist
deliveri
use
medicin
limit
need
simpl
reliabl
method
id
deliveri
id
inject
mantoux
techniqu
requir
special
train
may
reliabl
target
skin
nonetheless
use
current
bcg
rabi
vaccin
scarif
use
bifurc
needl
extens
use
smallpox
erad
provid
variabl
ineffici
deliveri
skin
recent
id
vaccin
simplifi
introduct
simpletous
hollow
microneedl
approv
id
inject
influenza
vaccin
europ
variou
design
hollow
microneedl
studi
preclin
human
vaccin
also
inject
skin
use
needlefre
devic
jet
inject
receiv
renew
clinic
attent
id
vaccin
projectil
deliveri
use
powder
gold
particl
ie
gene
gun
also
use
clinic
id
vaccin
build
scarif
approach
number
preclin
studi
examin
solid
microneedl
patch
use
vaccin
coat
onto
metal
microneedl
encapsul
within
dissolv
microneedl
ad
topic
skin
microneedl
pretreat
well
adapt
tattoo
gun
id
vaccin
final
technolog
design
increas
skin
permeabl
combin
vaccin
patch
studi
use
skin
abras
ultrasound
electropor
chemic
enhanc
thermal
ablat
prospect
bring
id
vaccin
widespread
clinic
practic
encourag
given
larg
number
technolog
id
deliveri
develop
skin
contain
high
concentr
antigenpres
cell
thu
site
capabl
induc
potent
immun
respons
skin
compos
multipl
layer
characterist
resid
transient
immun
cell
subset
outermost
thin
layer
epidermi
mm
primarili
made
epitheli
cell
well
langerhan
cell
melanocyt
merkel
cell
beneath
epidermi
dermi
thicker
layer
mm
consist
network
collagen
fiber
cell
adapt
innat
system
resid
circul
dermi
includ
macrophag
mast
cell
langerhan
cell
dermal
dendrit
cell
antigenpres
cell
skin
perform
essenti
role
process
incom
antigen
result
immun
system
activ
immun
toler
self
harmless
antigen
nicola
guy
reason
possibl
deliveri
vaccin
epidermi
dermi
may
result
superior
immun
respons
compar
anatom
site
glenn
kenney
lambert
laurent
nicola
guy
altern
equival
immun
respons
could
stimul
deliveri
smaller
quantiti
vaccin
antigen
skin
either
mechan
could
benefici
develop
vaccin
new
diseas
target
improv
immun
respons
hardtotreat
group
lower
cost
vaccin
antigen
may
particularli
valuabl
improv
access
vaccin
lowresourc
set
substanti
number
clinic
studi
evalu
intraderm
id
deliveri
vaccin
perform
major
studi
design
evalu
whether
id
deliveri
immunolog
superior
rout
case
simplifi
administr
reduc
dose
deliv
id
compar
full
dose
deliv
either
subcutan
sc
intramuscularli
im
studi
compar
deliveri
dose
vaccin
id
scim
research
need
establish
whether
potenti
dosespar
uniqu
id
deliveri
path
howev
id
deliveri
devic
develop
offer
addit
desir
featur
needlefre
deliveri
improv
eas
administr
may
driver
adopt
id
vaccin
deliveri
even
net
immunolog
benefit
vaccin
smallpox
deliv
skin
date
back
edward
jenner
first
experi
demonstr
exposur
cowpox
could
protect
smallpox
infect
varieti
scarif
techniqu
devic
use
allow
viru
introduct
includ
knive
needl
scalpel
rotari
lancet
global
smallpox
erad
campaign
multidos
nozzl
jet
injector
bifurc
needl
use
id
vaccinia
viru
inocul
henderson
et
al
bacil
bcg
vaccin
tuberculosi
global
wide
deliv
id
vaccin
id
inject
needl
syring
commonli
use
method
area
bcg
also
deliv
skin
use
multipunctur
devic
new
version
bcg
develop
effort
improv
immun
protect
also
deliv
id
hoft
et
al
rabi
vaccin
convent
deliv
im
due
high
cost
cellculturederiv
vaccin
press
need
afford
vaccin
regimen
endem
region
id
deliveri
extens
studi
postexposur
prophylaxi
preexposur
prophylaxi
id
regimen
induc
protect
titer
recommend
id
deliveri
reduc
dose
rabi
vaccin
sinc
given
equival
dose
antigen
deliveri
dermi
appear
either
superior
equival
imsc
bernard
et
al
bernard
et
al
fishbein
et
al
phanuphak
et
al
detail
review
id
rabi
vaccin
found
elsewher
special
volum
id
immun
warrel
multipl
studi
reduceddos
deliveri
influenza
vaccin
conduct
provid
inform
clinic
data
potenti
dosespar
id
deliveri
one
studi
found
id
deliveri
lg
ha
per
influenza
strain
compar
immunogen
standard
im
dose
lg
ha
per
strain
belsh
et
al
later
comparison
lg
deliv
id
im
found
equival
respons
two
deliveri
rout
dose
belsh
et
al
trial
also
conduct
influenza
use
novel
microneedl
devic
aid
accur
id
deliveri
discuss
sect
id
deliveri
reduc
dose
hepat
b
vaccin
evalu
healthi
infant
child
adult
popul
well
immunocompromis
patient
group
metaanalys
conclud
seroconvers
rate
lower
fulldos
im
deliveri
although
respons
higher
children
femal
chen
gluud
sangar
et
al
dose
hepat
b
antigen
deliv
id
im
immun
respons
equival
rout
ayoola
miln
et
al
heijtink
et
al
coberli
et
al
rahman
et
al
hepat
vaccin
also
propos
possibl
target
reduceddos
id
deliveri
two
studi
found
reduc
dose
deliv
id
produc
compar
immun
respons
im
deliveri
third
indic
id
rout
inferior
brindl
et
al
carlsson
et
al
pancharoen
et
al
local
reactogen
observ
alumadjuv
formul
countri
id
origin
standard
rout
deliveri
inactiv
polioviru
vaccin
inject
depth
later
shift
im
wenig
papania
studi
found
id
deliveri
reduc
dose
capabl
induc
seroconvers
may
help
make
vaccin
afford
use
develop
countri
samuel
et
al
samuel
et
al
nirmal
et
al
recent
global
polio
erad
initi
work
determin
potenti
mode
deliveri
use
posterad
set
phaseout
oral
polio
vaccin
sever
studi
conduct
evalu
id
deliveri
measl
vaccin
mix
result
burland
kok
et
al
whittl
et
al
de
mora
et
al
howev
vaccin
dose
method
use
deliv
vaccin
vari
possibl
trial
use
older
gener
deliveri
technolog
deliv
vaccin
reliabl
dermi
path
transcutan
immun
measl
vaccin
coat
patch
also
attempt
although
salivari
siga
respons
observ
key
marker
immun
increas
neutral
serum
igg
detect
etchart
et
al
studi
conduct
deliv
attenu
yellow
fever
viru
vaccin
scarif
deliveri
mode
abandon
efficaci
low
recent
clinic
trial
compar
full
dose
sc
deliveri
vaccin
dose
deliv
id
mantoux
inject
found
equival
seroprotect
two
rout
rouken
et
al
extens
descript
id
vaccin
yellow
fever
provid
elsewher
special
volum
id
immun
rouken
et
al
number
vaccin
consid
id
deliveri
research
shown
reduc
id
dose
vaccin
diphtheriatetanuspertussi
tetanu
toxoid
tickborn
enceph
gener
compar
immun
respons
standard
dose
way
inject
stanfield
et
al
zoulek
et
al
zoulek
et
al
dimach
et
al
id
deliveri
also
investig
number
vaccin
develop
includ
vaccin
tuberculosi
enterotoxigen
e
coli
pandem
influenza
well
dna
vaccin
tradit
method
use
id
deliveri
vaccin
limit
may
hinder
adopt
id
deliveri
bifurc
needl
multipunctur
devic
use
success
deliveri
smallpox
bcg
vaccin
deliv
reproduc
quantiti
vaccin
antigen
dermi
therefor
unlik
appropri
deliveri
devic
new
vaccin
lambert
laurent
mantoux
method
insert
needl
shallow
angl
skin
also
inconsist
requir
addit
train
skill
perform
correctli
flynn
et
al
perceiv
difficulti
perform
id
inject
use
method
may
prevent
develop
vaccin
id
deliveri
new
gener
devic
discuss
rest
articl
may
improv
reliabl
id
deliveri
enabl
adopt
id
rout
vaccin
vaccin
administ
im
sc
use
hypoderm
needl
achiev
id
vaccin
convent
hypoderm
needl
use
employ
mantoux
techniqu
inject
skin
simpler
reliabl
id
inject
pursu
adapt
hypoderm
needl
technolog
well
novel
hollow
microneedl
devic
produc
microfabr
mantoux
techniqu
id
inject
method
character
needl
insert
degre
angl
approxim
mm
deep
dermi
inject
vaccin
drug
fig
method
develop
charl
mantoux
earli
centuri
use
identifi
tuberculosi
infect
id
inject
tuberculin
mantoux
howev
techniqu
requir
train
often
consid
inconsist
deliveri
method
thu
prevent
vaccin
maker
medic
practition
use
id
inject
common
immun
method
lambert
laurent
also
age
elasticityrel
skin
condit
signific
effect
adequ
placement
needl
dermi
tradit
id
inject
techniqu
laurent
et
al
thu
lead
inadequ
vaccin
disadvantag
mantoux
techniqu
inject
includ
inaccur
deliv
dosag
vaccin
vaccin
wastag
dead
space
needl
variabl
inject
success
use
differ
gaug
needl
flynn
et
al
moreov
success
rate
id
inject
untrain
personnel
found
howard
et
al
effort
reduc
train
requir
improv
reliabl
mantoux
inject
techniqu
intraderm
adapt
develop
path
seattl
wa
usa
nonprofit
intern
health
agenc
develop
advanc
health
technolog
low
resourc
set
sid
technolog
devic
fit
convent
hypoderm
needl
syring
limit
angl
depth
penetr
needl
skin
order
facilit
deliveri
dermi
overcom
limit
convent
id
inject
bectondickinson
bd
develop
micros
needl
insert
skin
vertic
unlik
angl
inject
mantoux
method
novel
microneedl
devic
studi
anim
human
subject
current
use
approv
influenza
vaccin
intanza
idflu
bd
microneedl
devic
call
soluvia
tm
use
gaug
microneedl
extend
mm
beyond
insert
depthlimit
tip
connect
prefil
syring
fig
microneedl
system
evalu
versu
convent
mantoux
techniqu
compar
deliveri
effici
safeti
human
subject
use
ultrasound
echographi
analysi
distribut
fluid
deliv
microneedl
seen
larger
mantoux
inject
control
addit
microneedl
system
high
id
administr
success
rate
studi
patient
complianc
safeti
microneedl
devic
show
promis
result
system
also
caus
fewer
occurr
injuri
papillari
dermi
lesser
pain
mantoux
inject
administ
easili
untrain
personnel
laurent
et
al
earlier
prototyp
bd
microneedl
use
mm
gaug
needl
test
rat
deliveri
influenza
vaccin
show
dose
spare
effect
compar
im
control
id
microneedl
administr
low
dose
lg
inactiv
viru
vaccin
induc
similar
serum
antibodi
respons
im
inject
dose
time
larger
lg
addit
use
microneedl
id
immun
splitviron
vaccin
season
strain
show
approxim
tenfold
dosespar
compar
im
immun
studi
id
immun
use
plasmid
dna
vaccin
encod
hemagglutinin
protein
influenza
viru
show
similar
dosespar
effect
multipl
immun
alarcon
et
al
bd
microneedl
also
use
deliv
live
attenu
vaccin
japanes
enceph
chimerivax
tm
je
nonhuman
primat
studi
id
microneedl
inject
compar
sc
inject
transcutan
microabras
see
sect
microneedl
id
inject
provid
best
consist
immun
respons
ie
neutral
antibodi
three
type
immun
studi
compar
anthrax
vaccin
deliveri
use
id
microneedl
immun
im
inject
intranas
deliveri
epiderm
deliveri
microabras
mice
lg
dose
rabbit
lg
dose
microneedl
id
vaccin
show
slightli
better
respons
murin
model
rout
use
treatment
rabbit
similar
respons
followup
id
immun
perform
compar
id
inject
im
inject
rang
dose
rabbit
model
lg
anthrax
vaccin
mikszta
et
al
prime
immun
id
inject
show
significantli
higher
immunogen
im
inject
use
lg
dosag
interestingli
id
inject
lg
show
statist
equival
respons
im
administr
lg
dose
administr
booster
immun
dosespar
phenomenon
continu
furthermor
aerosol
lethal
challeng
anthrax
spore
show
lg
id
inject
complet
protect
immun
rabbit
wherea
im
inject
dose
protect
rabbit
earli
prototyp
bd
microneedl
system
first
test
clinic
studi
examin
influenza
vaccin
deliveri
healthi
adult
yr
elderli
adult
yr
belsh
et
al
studi
lg
hemagglutinin
deliv
id
inject
compar
full
dose
lg
deliv
im
immun
found
younger
particip
id
immun
significantli
differ
immun
im
shown
geometr
mean
hemagglutin
inhibit
hai
titer
howev
id
administr
show
lower
hai
titer
im
elderli
patient
evalu
id
microneedl
vaccin
influenza
perform
clinic
studi
healthi
adult
yr
lerouxroel
et
al
beran
et
al
elderli
person
yr
holland
et
al
arnou
et
al
healthi
adult
lg
hemagglutinin
b
strain
deliv
id
inject
compar
lg
im
immun
studi
confirm
previou
result
reduceddos
id
inject
equal
immunogen
fulldos
im
inject
lerouxroel
et
al
phase
ii
clinic
trial
effect
lower
dose
id
immun
investig
use
lg
hemagglutinin
id
lg
hemagglutinin
im
id
immun
use
lg
hemagglutinin
induc
inferior
immun
respons
shown
hai
titer
dose
lg
show
compar
respons
compar
fulldos
lg
im
vaccin
beran
et
al
elderli
subject
year
old
booster
vaccin
lg
administ
due
inferior
immun
system
gener
found
elderli
compar
younger
adult
goodwin
et
al
therefor
lg
hemagglutinin
administ
twice
either
id
im
rout
elderli
subject
phase
ii
clinic
trial
id
immun
show
significantli
better
immun
respons
determin
postimmun
gmt
geometr
mean
titer
seroprotect
particip
hai
titer
gmtr
geometr
mean
ratio
postimmun
titer
preimmun
titer
rate
seroconvers
postimmun
titer
particip
preimmun
titer
therefor
id
microneedl
vaccin
provid
superior
immunogen
high
prioriti
popul
protect
influenza
due
high
vulner
holland
et
al
find
confirm
phase
iii
clinic
trial
elderli
person
year
old
id
immun
show
superior
seroprotect
gmtr
rate
seroconvers
compar
im
prime
immun
administr
two
booster
immun
id
immun
induc
consist
higher
seroprotect
rate
im
immun
arnou
et
al
final
note
id
immun
caus
local
inflammatorylik
reaction
im
immun
possibl
id
deliveri
occur
skin
inflammatori
immunolog
reaction
easili
visibl
may
occur
im
immun
present
antigen
deep
muscl
layer
inflammatori
reaction
would
visibl
eye
belsh
et
al
holland
et
al
arnou
et
al
beran
et
al
van
damm
et
al
hollow
microneedl
also
develop
multineedl
array
involv
shorter
needl
mm
produc
novel
microfabr
techniqu
includ
laser
micromachin
davi
et
al
siliconbas
mem
techniqu
use
deep
reactiveion
etch
gardeni
et
al
roxh
et
al
integr
lithograph
mold
techniqu
luttg
et
al
deep
xray
photolithographi
perenn
et
al
photolithographi
micromold
techniqu
draw
lithographi
viscoelast
polym
other
addit
glass
hollow
microneedl
fabric
drawn
glass
micropipett
techniqu
wang
et
al
recent
develop
hollow
microneedl
array
micronjet
nanopass
technolog
use
human
clinic
trial
involv
healthi
adult
devic
consist
row
four
hollow
silicon
microneedl
lm
length
fig
studi
id
inject
array
use
im
dose
lg
induc
similar
immun
respons
measur
gmt
increas
seroconvers
rate
seroprotect
rate
id
deliveri
also
achiev
via
jet
inject
particl
inject
rout
needlefre
method
vaccin
drug
deliveri
decad
clinic
experi
jet
inject
recent
studi
conduct
newer
innov
technolog
needlefre
jet
injector
creat
fine
stream
pressur
liquid
penetr
skin
depth
deliveryid
sc
imi
larg
determin
design
variabl
inject
stream
coher
qualiti
pressur
orific
size
skin
tissu
thick
angl
inject
rel
skin
schrammbaxt
mitragotri
wenig
papania
vaccin
shown
achiev
immun
administ
via
jet
inject
convent
depth
ie
id
sc
im
depend
vaccin
includ
typhoid
cholera
bcg
tetanusdiphtheria
adult
whole
cell
diphtheriatetanuspertussi
dtp
measl
meningococc
c
smallpox
yellow
fever
hepat
hepat
b
influenza
plagu
polio
tetanu
wenig
papania
histor
multius
nozzl
jet
injector
munji
devic
reusabl
nozzl
use
success
worldwid
latter
half
centuri
deliv
countless
million
estim
billion
dose
vaccin
adult
children
cours
sever
decad
wenig
papania
respons
risk
diseas
transmiss
due
cross
contamin
reus
inject
devic
new
gener
jet
injector
design
develop
start
late
address
safeti
concern
new
jet
injector
util
steril
dispos
cartridg
syring
patient
inject
reusabl
handpiec
reli
power
sourc
manual
power
spring
ga
canist
number
disposablesyring
jet
injector
dsji
develop
approv
nation
regulatori
author
varieti
applic
use
includ
vaccin
deliveri
lowcost
manual
power
dsji
technolog
develop
specif
applic
develop
countri
immun
requir
need
includ
design
featur
prevent
reus
autodis
needlefre
syring
dsji
clinic
develop
id
deliveri
includ
biojector
zetajet
bioject
pharmajet
pharmajet
inc
long
histori
id
deliveri
via
jet
injector
rout
use
modifi
syring
orific
nozzl
either
direct
contact
skin
involv
setback
featur
spacer
intend
introduc
gap
nozzl
orific
inject
site
therebi
weaken
inject
stream
limit
deposit
dermal
space
wenig
papania
fig
b
munji
devic
provid
million
id
smallpox
dose
implement
smallpox
erad
program
millar
foeg
wenig
papania
jet
injector
also
util
histor
id
vaccin
rabi
bernard
et
al
bernard
et
al
hepat
william
et
al
bcg
paul
et
al
parker
dtp
combin
vaccin
stanfield
et
al
measl
burland
kok
et
al
influenza
vaccin
wenig
papania
number
studi
soon
implement
address
applic
dsji
id
deliveri
vaccin
import
global
public
health
exampl
us
center
diseas
control
prevent
lead
studi
season
influenza
vaccin
deliv
id
via
dsji
technolog
children
month
age
studi
compar
full
fraction
dose
im
id
vaccin
resultstod
indic
inject
gener
toler
studyrel
advers
event
initi
blind
assay
result
demonstr
compar
immun
respons
rate
final
studi
result
analysi
found
gomez
et
al
global
polio
erad
initi
work
determin
potenti
dsji
id
deliveri
inactiv
polioviru
vaccin
ipv
use
posterad
set
phase
use
oral
polio
vaccin
studi
conduct
oman
cuba
india
evalu
reduc
fraction
dose
ipv
deliv
two
differ
dsji
devic
compar
im
inferior
seroconvers
rate
found
id
dose
deliv
id
spacer
white
portion
end
syring
use
investig
use
courtesi
bioject
b
jet
injector
appli
skin
inject
courtesi
pharmajet
c
epiderm
powder
immun
devic
id
projectil
inject
courtesi
powderm
week
age
noninferior
rate
protect
seen
use
later
month
schedul
ipv
use
booster
oral
polio
vaccin
inferior
seroconvers
rate
observ
id
compar
im
deliveri
sutter
moham
et
al
resik
et
al
dsji
technolog
also
use
deliveri
dna
vaccin
malaria
young
adult
epstein
et
al
wang
et
al
hivvaccin
candid
path
pilot
studi
assess
human
papillomaviru
vaccin
also
recent
occur
path
path
also
work
implement
new
studi
purifi
vero
cell
rabi
vaccin
id
postexposur
prophylaxi
use
dsji
technolog
india
result
studi
anticip
vaccin
trial
id
vaccin
deliveri
plan
applic
includ
bcg
ipv
varicella
zoster
viru
yellow
fever
path
epiderm
powder
immun
epi
particlemedi
epiderm
deliveri
pmed
util
helium
ga
deliv
powder
protein
polysaccharid
inactiv
pathogen
dnacoat
particl
epidermi
superson
speed
wenig
papania
fig
compani
involv
develop
technolog
includ
powderject
powderm
acquir
pfizer
iaculor
inject
known
devic
technolog
class
still
activ
develop
path
convent
protein
antigen
must
special
formul
deliveri
epi
spray
dri
powder
suitabl
densiti
size
lm
clinic
trial
conduct
evalu
deliveri
powder
inactiv
influenza
vaccin
epi
inject
found
immunogen
compar
standard
deliveri
im
needl
syring
epi
also
shown
efficaci
preclin
studi
hepat
b
hiv
vaccin
chen
et
al
osorio
et
al
pmed
gold
bead
lm
diamet
coat
vaccin
deliv
needlefre
jet
inject
epidermi
approach
may
particularli
suit
dna
vaccin
deposit
coat
particl
stratum
corneum
epidermi
may
encourag
dna
uptak
express
resid
antigenpres
cell
dna
vaccin
hepat
b
deliv
pmed
induc
protect
antibodi
roy
et
al
robert
et
al
clinic
studi
also
conduct
dna
vaccin
season
influenza
evalu
feasibl
approach
result
promis
immun
respons
yet
equival
standard
vaccin
deliveri
method
drape
et
al
jone
et
al
epi
pmed
deliveri
dna
vaccin
varieti
diseas
also
shown
immunogen
preclin
includ
malaria
avian
influenza
herp
simplex
viru
hiv
nonsmal
cell
lung
cancer
eurasian
encephalit
virus
hantavirus
sar
coronaviru
smallpox
wenig
papania
year
variou
sharp
instrument
use
vaccin
creat
small
hole
skin
allow
vaccin
penetr
bodi
wenig
papania
although
vaccin
administr
current
perform
hypoderm
needl
inject
sharp
tool
bifurc
needl
histor
use
smallpox
frey
et
al
bcg
darmang
et
al
vaccin
remain
use
day
past
decad
new
skin
pierc
technolog
id
drug
transport
develop
includ
techniqu
microneedl
prausnitz
tattoo
bin
et
al
recent
method
especi
microneedl
shown
promis
deliv
vaccin
skin
therebi
enabl
improv
immunogen
simpler
patient
administr
bifurc
needl
fig
invent
benjamin
rubin
smallpox
vaccin
consist
two
sharp
prong
hold
vaccin
fluid
capillari
action
two
tine
use
devic
simpl
requir
train
personnel
baxbi
wenig
papania
needl
dip
vaccin
punctur
perpendicularli
skin
repeatedli
area
mm
diamet
process
call
scarif
although
method
effect
smallpox
erad
program
poorli
control
dose
ineffici
use
vaccin
needlestick
injuri
signific
shortcom
limit
use
bifurc
needl
vaccin
addit
hollow
microneedl
discuss
sect
solid
microneedl
use
pierc
skin
therebi
deposit
vaccin
epiderm
andor
dermal
space
techniqu
vaccin
use
solid
microneedl
includ
use
microneedl
penetr
skin
make
hole
vaccin
transport
vaccin
formul
may
place
skin
microneedl
penetr
coat
onto
microneedl
embed
within
microneedl
releas
skin
insert
solid
microneedl
prepar
patch
easili
appli
skin
perhap
self
administr
coat
microneedl
extens
studi
techniqu
id
microneedl
vaccin
fig
b
use
approach
vaccin
form
solidst
coat
surfac
solid
microneedl
dissolv
within
skin
upon
applic
typic
method
provid
bolu
deliveri
submilligram
dose
antigen
within
minut
applic
often
suitabl
deliveri
vaccin
effect
microneedl
coat
process
typic
involv
dipcoat
metal
microneedl
coat
solut
contain
vaccin
surfact
promot
wet
microneedl
surfac
viscos
enhanc
increas
coat
thick
gill
prausnitz
gill
prausnitz
use
techniqu
compound
larg
rang
size
includ
small
molecul
protein
dna
viru
particl
coat
onto
microneedl
novel
coat
microneedl
design
improv
deliveri
demonstr
threedimension
groovesembed
microneedl
han
et
al
pocket
microneedl
gill
prausnitz
first
id
vaccin
use
coat
microneedl
deliv
ovalbumin
model
protein
antigen
courtesi
univers
queensland
b
array
solid
stainless
steel
microneedl
coat
yellow
dye
mm
mm
devic
contain
microneedl
measur
lm
tall
inset
show
magnifi
view
two
coat
microneedl
courtesi
georgia
institut
technolog
c
dissolv
microneedl
shown
intact
insert
skin
partial
dissolv
min
insert
skin
fulli
dissolv
min
insert
skin
reproduc
sullivan
et
al
courtesi
georgia
institut
technolog
hairless
guinea
pig
matriano
et
al
widera
et
al
studi
id
microneedl
vaccin
show
better
immun
respons
equival
sc
im
inject
low
dose
investig
also
found
immun
respons
microneedl
vaccin
dosedepend
among
variou
vaccin
candid
influenza
vaccin
receiv
attent
id
immun
use
small
array
coat
microneedl
measur
approxim
lm
length
zhu
et
al
microneedl
coat
lg
season
influenza
inactiv
viru
vaccin
induc
complet
protect
lethal
viru
infect
mice
howev
subsequ
studi
show
influenza
vaccin
lost
antigen
coat
process
kim
et
al
order
maintain
antigen
disaccharid
trehalos
ad
coat
formul
serv
stabil
enabl
success
immun
requir
smaller
dose
vaccin
lg
compar
immun
similar
immun
respons
convent
im
immun
kim
et
al
coat
microneedl
also
show
improv
thermal
stabil
vaccin
compar
liquid
form
vaccin
kim
et
al
detail
studi
show
coat
microneedl
vaccin
inactiv
influenc
viru
vaccin
induc
similar
antibodi
igg
respons
hai
titer
neutral
activ
convent
im
immun
mice
kim
et
al
account
antigen
chang
vaccin
coat
process
vaccin
coat
microneedl
dissolv
needl
deliv
im
inject
case
vaccin
use
microneedl
show
better
primari
immun
respons
correspond
im
immun
use
antigen
formul
vaccin
coat
microneedl
induc
robust
immun
influenza
challeng
mous
model
kim
et
al
notabl
microneedleimmun
mice
shown
undetect
level
influenza
viru
titer
lung
challeng
unlik
im
immun
mice
viru
titer
least
higher
addit
assay
immun
respons
correspond
lung
sampl
lung
cytokin
lung
igg
also
consist
show
microneedl
immun
superior
im
evid
microneedleenhanc
immun
system
memori
respons
microneedl
immun
group
found
significantli
higher
level
total
igg
isotyp
postchalleng
prechalleng
antibodi
level
im
immun
mice
lower
postchalleng
prechalleng
kim
et
al
addit
improv
humor
immun
coat
microneedl
also
induc
cellular
recal
respons
mhc
iiassoci
helper
cell
respons
final
microneedl
immun
perform
use
differ
strain
influenza
viru
vaccin
induc
similar
complet
protect
lethal
challeng
koutsonano
et
al
studi
use
viruslik
particl
vlp
vaccin
coat
microneedl
also
perform
vlp
dose
control
use
coat
formul
includ
antigen
concentr
number
coat
dip
kim
et
al
lg
dose
vlp
deliv
microneedl
vaccin
induc
stronger
immun
respons
im
measur
igg
igg
subtyp
hai
neutral
activ
lung
igg
lung
cytokin
suppress
lung
viru
infect
microneedl
immun
vlp
show
complet
protect
lethal
viral
challeng
without
major
bodi
weight
loss
unlik
im
dose
partial
protect
mice
lethal
viral
infect
caus
signific
bodi
weight
loss
quan
et
al
novel
approach
coat
microneedl
involv
use
polyphosphazen
pcpp
serv
effect
coat
excipi
immun
adjuv
id
microneedl
immun
hepat
b
surfac
antigen
hbsag
pig
use
pcpp
coat
formul
superior
induc
antigenspecif
igg
compar
id
inject
hypoderm
needl
without
pcpp
anoth
studi
demonstr
effect
gener
cellular
immun
respons
hepat
c
dna
vaccin
administ
mice
use
coat
microneedl
gill
et
al
studi
sought
specif
target
deliveri
antigenpres
langerhan
cell
use
extrem
short
lm
needl
penetr
epidermi
short
needl
coat
use
novel
coat
process
involv
gasjet
dri
chen
et
al
initi
studi
vaccin
ovalbuminco
needl
induc
similar
immun
respons
im
immun
followup
studi
microneedl
coat
low
dose
hemagglutininbas
influenza
vaccin
gener
similar
immun
respons
im
vaccin
larger
dose
author
propos
short
dens
pack
microneedl
could
deliv
half
antigen
directli
antigenpres
cell
epiderm
langerhan
cell
dermal
dendrit
cell
fernando
et
al
method
longterm
vaccin
storag
without
signific
immunogen
loss
especi
without
refriger
import
vaccin
campaign
microneedl
coat
vaccin
solid
state
expect
confer
thermal
stabil
stabil
studi
microneedl
coat
inactiv
influenza
vaccin
mice
immun
coat
microneedl
store
room
temperatur
month
produc
similar
igg
respons
mice
immun
microneedl
store
day
furthermor
group
complet
protect
lethal
challeng
viral
infect
vitro
assay
microneedl
howev
show
decreas
antigen
kim
et
al
improv
coat
microneedl
dissolv
microneedl
develop
order
elimin
sharp
biohazard
wast
vaccin
fig
unlik
nondissolv
eg
metal
microneedl
coat
vaccin
formul
dissolv
microneedl
made
sole
materi
polym
sugar
safe
dissolv
skin
insert
leav
behind
microneedl
patch
back
typic
vaccin
incorpor
matrix
microneedl
releas
skin
upon
microneedl
dissolut
dissolv
microneedl
made
use
number
differ
materi
includ
polyvinylpyrrolidon
sullivan
et
al
maltos
kolli
banga
carboxymethylcellulos
lee
et
al
polylact
andor
polyglycol
acid
park
et
al
park
et
al
dextrin
ito
et
al
recent
studi
dissolv
microneedl
prepar
encapsul
inactiv
influenza
vaccin
polyvinylpyrrolidon
matrix
use
immun
mice
vaccin
gentli
encapsul
without
signific
damag
immunogen
shown
gener
similar
antibodi
cellular
immun
respons
compar
im
inject
dose
provid
complet
protect
lethal
challeng
compar
im
inject
dissolv
microneedl
vaccin
result
effici
lung
viru
clearanc
enhanc
cellular
recal
respons
challeng
sullivan
et
al
theraject
also
develop
biodegrad
microneedl
use
carboxymethylcellulos
contain
variou
biomolecul
includ
influenza
vaccin
oh
et
al
simpler
albeit
probabl
less
effici
method
microneedl
use
pierc
skin
make
permeabl
therebi
enabl
entri
topic
appli
vaccin
method
attract
microscal
pore
made
microneedl
insert
gener
small
penetr
microorgan
donnelli
et
al
yet
larg
enough
deliveri
subunit
possibl
viral
vaccin
insert
remov
microneedl
vaccin
appli
use
patch
topic
formul
slow
deliveri
diffus
longliv
pore
kalluri
banga
approach
investig
transcutan
vaccin
use
diphtheria
toxoid
influenza
vaccin
ding
et
al
ding
et
al
diphtheria
toxoid
appli
microneedlepretr
skin
combin
cholera
toxin
adjuv
similar
immun
respons
induc
compar
sc
inject
howev
microneedl
pretreat
enhanc
immun
respons
influenza
vaccin
vaccin
approach
also
studi
ex
vivo
human
skin
model
investig
skin
immun
cell
respons
ng
et
al
use
relat
approach
blunttip
microneedl
use
scrape
skin
therebi
make
microtrough
skin
dna
vaccin
encod
hbsag
administ
mikszta
et
al
approach
gener
stronger
humor
cellular
immun
respons
im
id
inject
tattoo
gun
use
highfrequ
oscil
needl
make
thousand
punctur
skin
convent
use
deposit
tattoo
ink
dermi
adapt
deliv
id
vaccin
fig
one
studi
hemagglutininexpress
dna
vaccin
administ
pig
deriv
humor
protect
immun
shown
method
includ
hai
titer
improv
viru
clearanc
nasal
swab
eriksson
et
al
overcom
slow
process
immun
respons
induc
dna
vaccin
dna
tattoo
suggest
shortinterv
dna
vaccin
bin
et
al
studi
shown
shortinterv
id
dna
tattoo
immun
gener
fast
stabl
cell
respons
human
papillomaviru
complet
protect
influenza
viru
challeng
compar
im
rout
dna
tattoo
vaccin
elicit
much
stronger
quicker
humor
cellular
immun
respons
addit
studi
indic
even
im
immun
adjuv
inferior
dna
tattoo
immun
pokorna
et
al
determin
effect
tattoo
process
dna
vaccin
stabil
dna
topolog
chang
evalu
includ
critic
factor
antigen
express
immun
respons
quaak
et
al
found
dna
tattoo
tool
neglig
effect
dna
structur
activ
vaccin
includ
adenovir
vector
vaccin
respiratori
syncyti
viru
potthoff
et
al
peptid
vaccin
human
papillomaviru
pokorna
et
al
administr
id
tattoo
case
adenovir
vector
vaccin
tattoo
show
similar
perform
id
inject
tattoo
peptid
vaccin
cpg
motif
adjuv
show
better
respons
im
vaccin
adjuv
dna
tattoo
evalu
nonhuman
primat
previous
shown
poor
dna
vaccin
immun
effect
show
remark
enhanc
immun
respons
method
administ
hiv
vaccin
verstrepen
et
al
order
advanc
techniqu
human
clinic
trial
human
ex
vivo
skin
model
test
show
dna
concentr
critic
factor
effect
dna
vaccin
tattoo
van
den
human
clinic
trial
treat
melanoma
plan
quaak
et
al
comprehens
review
dna
tattoo
found
one
accompani
paper
special
volum
id
immun
oosterhui
et
al
id
vaccin
method
describ
far
involv
minim
invas
needlebas
method
noninvas
jetbas
method
activ
deposit
vaccin
within
skin
anoth
set
approach
involv
mostli
noninvas
method
increas
skin
permeabl
enabl
vaccin
transport
skin
transient
permeabil
state
key
success
use
approach
disrupt
skin
outer
layer
call
stratum
corneum
although
stratum
corneum
lm
thick
provid
highli
effect
barrier
permeat
xenogen
includ
topic
appli
vaccin
formul
scheuplein
blank
number
method
increas
skin
permeabl
develop
larg
drug
deliveri
applic
mani
test
vaccin
mitragotri
prausnitz
langer
number
studi
demonstr
skin
barrier
broken
abras
varieti
abras
method
includ
rough
surfac
frerich
et
al
tapestrip
takigawa
et
al
peachman
et
al
inou
aramaki
vandermeulen
et
al
microdermabras
devic
shown
induc
adequ
remov
stratum
corneum
repeat
peel
tape
exampl
scotch
tape
effect
remov
stratum
corneum
applic
tumor
epitop
peptid
tapestrip
mous
skin
prime
tumorspecif
cytotox
cell
lymph
node
spleen
protect
mice
subsequ
challeng
correspond
tumor
cell
also
suppress
growth
establish
tumor
takigawa
et
al
skin
abras
use
razor
toothbrush
follow
applic
adenovir
vector
yield
promis
result
human
van
kampen
et
al
skin
abras
use
abras
paper
perhap
commonli
use
method
disrupt
stratum
corneum
immun
exampl
abras
emeri
paper
skin
hydrat
shown
induc
adequ
penetr
anthrax
vaccin
matya
et
al
influenza
viru
vaccin
guebrexabi
et
al
among
other
led
develop
skin
prep
system
sp
provid
control
method
stratum
corneum
disrupt
transcutan
immun
current
develop
intercel
frerich
et
al
fig
techniqu
shown
effect
human
specif
skin
prepar
use
two
mild
stroke
skin
prepar
devic
contain
mild
abras
affix
pressurecontrol
devic
devic
singleus
dispos
system
discard
immedi
use
follow
skin
prepar
patch
contain
vaccin
travel
diarrhea
lt
patch
appli
within
mark
area
worn
h
vaccin
remov
discard
particip
ltpatch
recipi
protect
moderatetosever
diarrhea
protect
efficaci
sever
diarrhea
protect
efficaci
ltpatch
recipi
becam
ill
shorter
episod
diarrhea
vs
day
fewer
loos
stool
placebo
anoth
studi
similar
techniqu
use
boost
respons
influenza
vaccin
case
prior
applic
patch
area
lightli
abrad
ecggrad
emeri
paper
skin
wet
alcohol
disrupt
stratum
corneum
week
follow
vaccin
hemagglutin
inhibit
hai
respons
lt
immunostimulatori
patch
recipi
show
improv
receiv
vaccin
alon
frech
et
al
microdermabras
common
cosmet
procedur
adapt
remov
superfici
skin
layer
sandblast
therebi
enabl
select
remov
stratum
corneum
barrier
approach
shown
increas
skin
permeabl
therebi
enabl
topic
applic
live
attenu
vaccinia
viru
microdermabrad
skin
gener
virusspecif
antibodi
blood
mention
sect
microneedlebas
abras
method
also
success
use
vaccin
ultrasound
especi
low
frequenc
effect
permeabil
skin
tezel
et
al
understood
acoust
cavit
format
pulsat
collaps
gaseou
bubbl
oscil
pressur
field
ultrasound
princip
mediat
ultrasoundinduc
enhanc
skin
permeabl
sever
studi
shown
ultrasound
exposur
transient
cavit
predominantli
induc
coupl
medium
liquid
present
ultrasound
transduc
skin
primarili
respons
skin
permeabil
tang
et
al
tezel
et
al
tezel
mitragotri
estim
bubbl
collapsesscm
form
symmetr
collaps
fig
skin
permeabil
method
skin
abras
devic
sandpap
devic
place
skin
scrape
across
skin
control
fashion
vaccin
patch
appli
abrad
skin
courtesi
intecel
b
handheld
skin
electropor
devic
use
microneedl
electrod
caus
highli
local
electropor
skin
facilit
dna
vaccin
deliveri
skin
cell
courtesi
cyto
puls
scienc
c
heatbas
devic
thermal
ablat
skin
microheat
array
left
side
inset
use
ablat
skin
vaccin
patch
right
side
inset
appli
ablat
skin
courtesi
altea
therapeut
gener
shock
wave
asymmetr
collaps
produc
microjet
near
surfac
skin
suffici
explain
experimentallyobserv
skin
permeabl
enhanc
ultrasoundinduc
skin
permeabil
ultrasound
shown
enhanc
deliveri
vaccin
skin
tezel
et
al
studi
perform
mice
shown
immun
respons
gener
ultrason
deliv
vaccin
greater
compar
sc
inject
per
unit
dose
vaccin
enter
skin
topic
appli
dose
enter
skin
tezel
et
al
compar
simpl
topic
administr
ultrasound
pretreat
show
increas
vaccin
deliveri
therebi
enabl
suffici
vaccin
enter
skin
activ
immun
respons
furthermor
applic
ultrasound
result
activ
langerhan
cell
reason
behind
clear
anoth
studi
shown
applic
tetanu
toxoid
skin
pretreat
ultrasound
gener
antitetanu
toxoid
igg
neutral
antibodi
titer
dahlan
et
al
sever
paramet
includ
concentr
coappli
sodium
dodecyl
sulfat
ultrasound
duti
cycl
impact
magnitud
antibodi
titer
author
conclud
main
mechan
ultrasoundassist
skin
immun
involv
factor
addit
enhanc
skin
permeabl
topic
appli
antigen
electropor
involv
applic
highvoltag
shortdur
electr
puls
transient
disrupt
lipid
barrier
bodi
vaccin
electropor
use
increas
stratum
corneum
permeabl
therebi
enabl
vaccin
entri
skin
electropor
also
use
permeabil
cell
within
skin
therebi
drive
exampl
dna
vaccin
epiderm
dermal
cell
fig
electropor
well
establish
tool
deliv
molecul
across
stratum
corneum
prausnitz
et
al
across
cell
membran
bilitewski
et
al
mani
studi
focus
use
electropor
dna
vaccin
surpris
given
long
histori
use
electropor
deliveri
dna
cell
vitro
howev
mani
electropor
studi
involv
insert
electrod
needl
skin
studi
demonstr
use
electropor
topic
vaccin
deliveri
zhao
et
al
one
studi
electropor
found
stimul
exodu
langerhan
cell
skin
like
adjuvantlik
effect
zhao
et
al
studi
efficaci
peptid
deliveri
found
compar
id
inject
freund
complet
adjuv
peptidespecif
ctl
respons
vaccin
deliv
electropor
equival
deliv
id
inject
electropor
shown
induc
effect
immun
respons
deliveri
dna
vaccin
peachman
et
al
foldvari
et
al
medi
singh
vandermeulen
et
al
exampl
studi
pig
shown
abil
electropor
deliv
hbsag
gene
use
singleneedl
sixneedl
electrod
babiuk
et
al
studi
demonstr
vivo
skin
electropor
may
use
increas
transgen
express
rel
nake
dna
inject
drabick
et
al
transfect
cell
princip
locat
dermi
includ
adipocyt
fibroblast
endotheli
cell
numer
mononuclear
cell
dendrit
process
porcin
model
transfect
cell
also
observ
lymph
node
drain
electropermeabil
site
hbsagcod
plasmid
use
test
skin
electroporationmedi
nucleic
acid
vaccin
murin
model
applic
find
includ
modul
immun
respons
pathogen
allergen
tumorassoci
antigen
modif
toler
anoth
studi
vivo
electropor
shown
protect
avian
influenza
nonhuman
primat
laddi
et
al
number
human
clinic
trial
test
vaccin
enhanc
electropor
current
way
sever
chemic
known
interact
skin
disrupt
highli
order
lipid
bilay
structur
stratum
corneum
observ
led
studi
chemic
agent
enhanc
transport
across
skin
chemic
studi
abil
increas
skin
permeabl
karand
et
al
chemic
permeat
enhanc
rel
inexpens
easi
formul
offer
flexibl
design
simpl
applic
allow
freedom
selfadministr
patient
chemic
enhanc
compris
wide
varieti
differ
chemic
function
group
facilit
drug
transport
across
skin
varieti
complex
mechan
directli
exert
effect
skin
structur
act
intercellular
lipid
corneocyt
chemic
enhanc
extract
lipid
skin
therebi
creat
diffus
pathway
transderm
permeat
altern
partit
lipid
bilay
therebi
disrupt
highli
order
lipid
lamella
caus
fluidiz
chemic
enhanc
also
significantli
increas
skin
transport
drug
enhanc
thermodynam
activ
formul
karand
et
al
recent
chemic
enhanc
shown
possess
abil
deliv
antigen
gener
immun
respons
achiev
design
formul
possess
abil
enhanc
skin
permeabl
well
exhibit
high
adjuvant
ration
design
multifunct
formul
first
principl
requir
indepth
knowledg
interact
chemic
enhanc
skin
exist
limit
pool
chemic
henc
combinatori
librari
chemic
mixtur
screen
studi
shown
randomli
select
popul
chemic
formul
certain
binari
mixtur
chemic
far
potent
permeabil
skin
compar
singl
chemic
karand
et
al
vaccin
studi
third
chemic
ad
goal
enhanc
abil
offer
adjuvant
lead
chemic
formul
test
mice
use
model
antigen
ovalbumin
formul
exhibit
high
permeat
adjuvant
potenti
vitro
screen
also
induc
high
igg
titer
mice
karand
et
al
anoth
studi
penetr
enhanc
immunomodul
oleic
acid
retino
acid
use
enhanc
transcutan
immun
inactiv
influenza
viru
across
tapestrip
skin
skountzou
et
al
pretreat
mous
skin
oleic
acid
elicit
increas
level
influenza
virusspecif
bind
neutral
antibodi
level
equival
induc
intranas
immun
inactiv
influenza
viru
oleic
acid
retino
acid
treatment
differenti
affect
pattern
cytokin
product
upon
stimul
influenza
viral
antigen
provid
enhanc
protect
thermal
porat
skin
use
deliv
vaccin
skin
micropor
system
design
porat
skin
develop
number
compani
method
array
micropor
creat
skin
remov
stratum
corneum
applic
focus
thermal
energi
base
resist
heat
via
contact
electr
heat
smalldiamet
wire
skin
surfac
bramson
et
al
fig
method
base
radiofrequ
laserbas
approach
studi
micropor
tip
compris
set
lm
diamet
tungsten
wire
control
circuitri
allow
precis
control
electr
current
puls
pass
wire
softwar
user
interfac
design
enabl
control
variou
micropor
paramet
includ
micropor
densiti
resist
element
temperatur
current
puls
width
number
puls
puls
pace
contact
pressur
temperatur
tip
place
contact
skin
calibr
optic
calibr
devic
studi
show
micropor
significantli
increas
penetr
topic
deliv
vaccin
micropor
enhanc
express
luciferas
upon
placement
adenoviru
vector
procedur
led
increas
ctl
respons
increas
ifnc
secret
cell
relat
studi
technolog
shown
deliv
influenza
vaccin
mous
skin
eighti
micropor
creat
cm
area
vaccin
place
porat
skin
procedur
gener
adequ
protect
respons
mice
garg
et
al
id
vaccin
offer
potenti
immunolog
advantag
public
health
skin
known
site
rich
antigenpres
cell
specif
skin
includ
epiderm
langerhan
cell
dermal
dendrit
cell
glenn
kenney
addit
antigen
may
taken
directli
lymphat
vessel
transport
antigenpres
cell
lymph
node
minimum
id
rout
vaccin
appear
follow
differ
pathway
immun
compar
im
sc
rout
howev
evid
id
rout
differ
also
benefici
glenn
kenney
lambert
laurent
nicola
guy
possibl
dose
spare
enabl
id
vaccin
suggest
previou
preclin
clinic
studi
howev
success
applic
approach
yet
definit
confirm
mani
vaccin
glenn
kenney
lambert
laurent
nicola
guy
although
conclus
vari
differ
studi
differ
vaccin
indic
dose
spare
may
possibl
howev
current
clear
condit
skin
uniqu
immun
environ
har
optim
effect
addit
dose
spare
preclin
studi
evid
benefici
differ
id
vaccin
studi
microneedl
show
improv
influenza
viru
clearanc
lung
enhanc
memori
respons
compar
im
vaccin
kim
et
al
studi
epi
show
specif
role
langerhan
cell
gener
robust
antibodi
respons
studi
ultrasoundmedi
vaccin
suggest
adjuv
effect
skin
dahlan
et
al
id
vaccin
offer
potenti
valu
public
health
also
term
possibl
logist
advantag
comparison
im
sc
vaccin
carri
hypoderm
needl
inject
option
besid
jet
inject
id
vaccin
open
door
mani
technolog
skin
readili
access
surfac
bodi
result
id
inject
may
enabl
vaccin
method
gener
biohazard
sharp
wast
administ
personnel
minim
train
simplifi
transport
storag
logist
tabl
mantoux
techniqu
inject
requir
special
train
clinic
personnel
microneedl
system
patchbas
deliveri
accompani
skin
permeabil
technolog
offer
promis
simplifi
vaccin
method
requir
minim
train
may
permit
selfvaccin
patient
certain
scenario
benefit
routin
vaccin
scenario
especi
import
mass
vaccin
campaign
associ
diseas
erad
program
pandem
emerg
contrast
novel
id
deliveri
method
projectil
deliveri
tattoo
gun
introduc
new
sophist
devic
requir
addit
train
clinic
personnel
assum
inject
done
properli
mantoux
techniqu
administ
essenti
vaccin
skin
hollow
microneedl
projectil
deliveri
similarli
effici
howev
solid
microneedl
typic
retain
vaccin
devic
patchbas
skin
permeabil
method
extrem
ineffici
vaccin
typic
remain
skin
surfac
effici
vaccin
util
critic
import
new
costli
vaccin
well
develop
countri
vaccin
cost
signific
barrier
access
elimin
hypoderm
needl
vaccin
major
object
public
health
given
close
one
million
peopl
die
year
diseas
transmiss
contamin
needl
miller
pisani
kermod
microneedl
step
right
direct
still
gener
biohazard
sharp
wast
except
dissolv
microneedl
projectil
deliveri
patchbas
method
elimin
needl
therefor
offer
improv
safeti
profil
thermal
ablat
requir
littl
personnel
train
requir
personnel
train
requir
personnel
train
mainten
dedic
devic
b
almost
skin
skin
skin
c
biohazard
sharp
wast
microscop
biohazard
sharp
wast
macroscop
biohazard
sharp
wast
widespread
clinic
practic
publish
vaccin
data
human
preclin
e
reformul
requir
possibl
new
liquid
formul
requir
reformul
requir
produc
solidst
vaccin
f
inexpens
dispos
devic
specialti
dispos
devic
reusabl
devic
perinject
cost
reusabl
devic
depend
number
time
devic
use
cost
dispos
compon
howev
id
deliveri
method
caus
ad
tissu
trauma
skin
bremseth
pass
new
method
id
vaccin
requir
signific
technolog
develop
jet
inject
alreadi
widespread
clinic
use
mani
technolog
preclin
stage
develop
vaccin
said
mani
technolog
much
later
stage
develop
use
nonvaccin
applic
facilit
adapt
id
vaccin
new
id
vaccin
technolog
also
requir
vaccin
reformul
hollow
microneedl
jet
tattoobas
method
may
use
standard
current
avail
liquid
formul
case
need
concentr
otherwis
modifi
method
mostli
use
solidst
vaccin
formul
offer
like
advantag
term
vaccin
stabil
storag
howev
requir
signific
reformul
associ
research
regulatori
manufactur
hurdl
final
devic
cost
signific
consider
given
hypoderm
needl
syring
extrem
inexpens
dispos
devic
microneedl
system
patchbas
method
expect
low
manufactur
cost
mass
product
howev
mani
technolog
requir
multipl
devic
compon
may
engin
dispos
devic
ad
cost
reusabl
devic
dispos
compon
requir
initi
invest
amort
mani
patient
id
vaccin
alreadi
made
signific
impact
public
health
primari
mean
immun
smallpox
erad
continu
play
role
bcg
rabi
vaccin
current
clinic
practic
plotkin
et
al
howev
discuss
articl
mani
opportun
id
vaccin
potenti
improv
immunogen
simplifi
logist
administr
vaccin
number
new
id
vaccin
technolog
success
human
clinic
trial
id
vaccin
use
bd
hollow
microneedl
approv
europ
id
administr
sanofi
pasteur
season
influenza
vaccin
introduc
australia
new
zealand
influenza
season
holland
et
al
beran
et
al
microneedl
devic
may
adapt
use
administ
vaccin
well
jet
injector
long
histori
use
vaccin
receiv
renew
attent
id
deliveri
vaccin
clinic
trial
especi
address
develop
countri
need
support
us
center
diseas
control
prevent
see
sect
skin
abras
pretreat
appli
vaccin
patch
also
clinic
trial
prevent
influenza
travel
diarrhea
frech
et
al
frech
et
al
projectil
base
deliveri
epi
pmed
studi
number
human
clinic
trial
dna
proteinbas
vaccin
jone
et
al
although
unclear
extent
technolog
continu
commerci
develop
id
deliveri
devic
advanc
preclin
studi
solid
coat
microneedl
subject
numer
vaccin
studi
mice
larger
anim
administ
influenza
vaccin
see
sect
use
phase
ii
clinic
trial
drug
parathyroid
hormon
cosman
et
al
likewis
skin
electropor
case
combin
microneedl
studi
anim
skin
vaccin
evid
clinic
feasibl
electropor
skin
target
deliveri
chemotherapeut
agent
skin
tumor
approv
use
europ
gehl
tattoo
cours
widespread
human
use
applic
vaccin
studi
preclin
method
increas
skin
permeabl
ultrasound
chemic
enhanc
heat
also
clinic
use
trial
transderm
drug
deliveri
applic
prausnitz
langer
compliment
preclin
studi
use
vaccin
given
larg
number
technolog
id
vaccin
develop
advanc
clinic
statu
mani
futur
outlook
bring
id
vaccin
widespread
clinic
practic
appear
encourag
optim
deliveri
method
depend
specif
applic
factor
immunolog
respons
logist
need
financi
constraint
